Berlin, Germany – March 17, 2026 – A promising new avenue for treating amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease, has emerged from a Phase 2b clinical trial. Researchers have found that an experimental oral therapy, dubbed PrimeC, appears safe and well-tolerated in individuals living with ALS, with early indications suggesting potential clinical benefits. The findings, published today in JAMA Neurology, offer a glimmer of hope for those affected by this currently incurable condition and pave the way for larger-scale Phase 3 trials.
ALS, often referred to as Lou Gehrig’s disease, progressively destroys motor neurons, leading to muscle weakness, paralysis, and respiratory failure. The disease affects approximately 5 to 20 people per 100,000 globally, according to the ALS Association. Currently, treatment options are limited, focusing primarily on managing symptoms and slowing disease progression. The average life expectancy after diagnosis is typically two to five years, though some individuals may live much longer. This makes the potential of PrimeC, and therapies like it, particularly significant.
The study, conducted by researchers at the Mass General Brigham Neuroscience Institute and the Barrow Neurological Institute, both based in the United States, enrolled 68 participants. Participants were randomly assigned to receive either PrimeC or a placebo for six months, followed by a 12-month open-label extension phase where all participants received PrimeC. The research team focused on assessing the safety and tolerability of PrimeC, as well as looking for early signals of efficacy. Although the trial wasn’t powered to definitively prove PrimeC’s effectiveness, the initial results are encouraging.
What is PrimeC and How Does it Work?
PrimeC is a novel combination therapy consisting of celecoxib and ciprofloxacino. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) commonly used to treat pain and inflammation, while ciprofloxacino is a fluoroquinolone antibiotic. The rationale behind combining these two drugs is to target several key pathological processes believed to contribute to the development and progression of ALS. Researchers hypothesize that PrimeC works by combating neuroinflammation, reducing the accumulation of iron in the brain and spinal cord, and modulating the activity of microRNAs – small molecules that play a role in gene regulation.
The accumulation of iron, in particular, has been increasingly recognized as a significant factor in ALS pathogenesis. Excess iron can contribute to oxidative stress and neuronal damage. Similarly, neuroinflammation, an inflammatory response within the nervous system, is thought to exacerbate the disease process. MicroRNAs are involved in a wide range of cellular functions, and dysregulation of microRNA expression has been observed in ALS patients. By addressing these multiple pathways, PrimeC aims to provide a more comprehensive therapeutic approach.
During the six-month double-blind phase of the trial, participants receiving PrimeC experienced a slightly higher rate of adverse events (20.0%) compared to those receiving the placebo (4.3%). However, the majority of these side effects were mild to moderate in severity and transient, meaning they resolved on their own. This suggests that PrimeC is generally well-tolerated, which is a crucial factor for any potential long-term treatment.
Promising Functional and Clinical Outcomes
Whereas the study was not designed to definitively demonstrate efficacy, the researchers observed encouraging trends in functional outcomes. Participants in the PrimeC group showed improvements in their scores on the Revised ALS Functional Rating Scale (ALSFRS-R), a widely used measure of disease progression. At six months, the PrimeC group achieved an average score 2.23 points higher than the placebo group. More significantly, at 18 months, participants initially assigned to PrimeC had an average ALSFRS-R score 7.92 points higher than those who initially received the placebo. This suggests a sustained benefit with continued treatment.
the study indicated a potential reduction in the risk of complications associated with ALS. Participants treated with PrimeC experienced a 64% reduction in the risk of events such as hospitalization, respiratory failure, or death. While this finding requires confirmation in larger trials, it offers a compelling reason for further investigation.
Exploratory analyses of biomarkers – measurable indicators of biological processes – revealed additional insights. Participants in the PrimeC group exhibited lower levels of ferritin, a protein that stores iron in the body. This finding supports the hypothesis that PrimeC may be effective in reducing iron accumulation in the nervous system. The treatment was also associated with lower levels of specific microRNAs linked to ALS. Interestingly, no significant changes were observed in levels of neurofilament light chain, another biomarker often used to assess neuronal damage, between the two groups.
“The improvements in functional and biomarker signals that we observed support a Phase 3 study to evaluate the efficacy and safety of PrimeC in a larger population,” stated Dr. Merit Cudkowicz, the lead author of the study and Director of the Mass General Brigham Neuroscience Institute, in a press statement.
Next Steps and Hope for Patients
The urgency to develop effective therapies for ALS is paramount, given the devastating impact of the disease on patients and their families. The ALS Association estimates that over $300 million is spent annually in the United States on ALS care and research. The positive results from the PARADIGM trial provide a strong scientific rationale for advancing PrimeC into a Phase 3 clinical trial. This next phase will involve a larger number of participants and will be designed to definitively assess the efficacy and safety of the therapy.
Dr. Jeremy M. Shefner, Professor of Neurology at the Barrow Neurological Institute and a senior author of the publication, emphasized the consistency of the findings. “The most striking aspect of the PARADIGM study is that multiple clinical outcome measures suggest the same level of clinical benefit, and several biomarkers are consistent with those measures,” he explained. This convergence of evidence strengthens the case for PrimeC as a potential therapeutic agent.
The researchers are currently planning the Phase 3 trial, which will likely involve multiple clinical sites and a more diverse patient population. The timeline for initiating the Phase 3 trial is not yet fully defined, but researchers are aiming to commence enrollment as soon as possible. The success of this trial could potentially lead to a new treatment option for individuals living with ALS, offering hope for a better quality of life and potentially slowing disease progression.
Key Takeaways
- PrimeC, a combination of celecoxib and ciprofloxacino, shows promise as a potential treatment for ALS.
- The Phase 2b trial demonstrated that PrimeC is safe and well-tolerated in ALS patients.
- Participants receiving PrimeC exhibited improvements in functional outcomes and biomarker changes.
- A Phase 3 clinical trial is planned to confirm the efficacy and safety of PrimeC.
The ongoing research into ALS and the development of innovative therapies like PrimeC represent a critical step forward in the fight against this debilitating disease. The scientific community remains dedicated to finding effective treatments and a cure for ALS. The next major milestone will be the initiation of the Phase 3 trial, and updates on its progress will be closely watched by patients, families, and researchers alike.
Readers interested in learning more about ALS and supporting research efforts can visit the ALS Association website at https://www.als.org/. We encourage you to share this article with anyone who may be affected by ALS and to join the conversation in the comments below.